Peter Klare

5.8k total citations
89 papers, 1.3k citations indexed

About

Peter Klare is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Peter Klare has authored 89 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Oncology, 41 papers in Pulmonary and Respiratory Medicine and 23 papers in Surgery. Recurrent topics in Peter Klare's work include Cancer Treatment and Pharmacology (22 papers), Ovarian cancer diagnosis and treatment (21 papers) and Breast Cancer Treatment Studies (20 papers). Peter Klare is often cited by papers focused on Cancer Treatment and Pharmacology (22 papers), Ovarian cancer diagnosis and treatment (21 papers) and Breast Cancer Treatment Studies (20 papers). Peter Klare collaborates with scholars based in Germany, Egypt and United Kingdom. Peter Klare's co-authors include Stefan von Delius, Jalid Sehouli, W. Lichtenegger, Bernhard Haller, Roland M. Schmid, Roland M. Schmid, Oumar Camara, Dirk Stengel, Mohamed Abdelhafez and Jens‐Uwe Blohmer and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Peter Klare

87 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Klare Germany	19	754	372	340	313	207	89	1.3k
Enora Laas France	21	585 0.8×	184 0.5×	181 0.5×	228 0.7×	350 1.7×	97	1.5k
Caitlin C Morrison United States	9	790 1.0×	272 0.7×	440 1.3×	105 0.3×	194 0.9×	17	1.5k
Pierre-Étienne Heudel France	17	558 0.7×	319 0.9×	129 0.4×	107 0.3×	133 0.6×	95	990
Àngels Arcusa Spain	16	616 0.8×	302 0.8×	156 0.5×	104 0.3×	234 1.1×	34	1.0k
Atif A Hashmi Pakistan	22	461 0.6×	228 0.6×	336 1.0×	94 0.3×	336 1.6×	136	1.4k
Lucy Davies Australia	17	936 1.2×	642 1.7×	668 2.0×	81 0.3×	102 0.5×	28	1.6k
Emanuele Naglieri Italy	15	336 0.4×	200 0.5×	245 0.7×	196 0.6×	141 0.7×	42	1.0k
Maria Tolia Greece	20	487 0.6×	389 1.0×	253 0.7×	55 0.2×	206 1.0×	135	1.3k
Israel Zighelboim United States	23	320 0.4×	234 0.6×	440 1.3×	497 1.6×	242 1.2×	71	1.6k
Dimitris D. Tsiftsis Greece	19	282 0.4×	150 0.4×	433 1.3×	241 0.8×	98 0.5×	38	1.0k

Countries citing papers authored by Peter Klare

Since Specialization

Citations

This map shows the geographic impact of Peter Klare's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Klare with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Klare more than expected).

Fields of papers citing papers by Peter Klare

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Klare. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Klare. The network helps show where Peter Klare may publish in the future.

Co-authorship network of co-authors of Peter Klare

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Klare. A scholar is included among the top collaborators of Peter Klare based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Klare. Peter Klare is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wehrmann, Till, Andrea Riphaus, Alexander J. Eckardt, et al.. (2023). Aktualisierte S3-Leitlinie „Sedierung in der gastrointestinalen Endoskopie“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). Zeitschrift für Gastroenterologie. 61(9). 1246–1301. 4 indexed citations

Thill, Marc, Pauline Wimberger, Andrea Gräfe, et al.. (2022). Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958). Breast Cancer Research and Treatment. 196(2). 311–321. 2 indexed citations

Decker, Thomas, Ulrike Söling, Antje Hahn, et al.. (2020). Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer. BMC Cancer. 20(1). 286–286. 4 indexed citations

Reinisch, Mattea, Michael Untch, Toralf Reimer, et al.. (2020). 86P Patients (pts) preference for different administration methods of trastuzumab (T) in pts with HER2+ early breast cancer (BC) treated within the GAIN-2 trial. Annals of Oncology. 31. S44–S44. 1 indexed citations

Schneeweiß, Andreas, Volker Möbus, Hans Tesch, et al.. (2020). 160O Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC). Annals of Oncology. 31. S303–S304. 3 indexed citations

Hauke, Jan, Corinna Ernst, Peter A. Fasching, et al.. (2020). 176P Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA study (NCT02789332). Annals of Oncology. 31. S313–S313. 3 indexed citations

Haller, Bernhard, et al.. (2019). Near focus NBI endoscopy plus acetic acid for optical polyp characterization in the colorectum - A proof of principle study. Scandinavian Journal of Gastroenterology. 54(3). 377–383. 6 indexed citations

Gerber, B., Marcus Schmidt, Volker Moebus, et al.. (2019). Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study. The Breast. 45. 22–28. 12 indexed citations

Haller, Bernhard, Diana Mateus, Thierry Ponchon, et al.. (2018). Optical classification of neoplastic colorectal polyps – a computer-assisted approach (the COACH study). Scandinavian Journal of Gastroenterology. 53(9). 1100–1106. 34 indexed citations

10.

Zopf, Steffen, Clemens Neufert, Andreas Nägel, et al.. (2018). I-scan optical enhancement for the in vivo prediction of diminutive colorectal polyp histology: Results from a prospective three-phased multicentre trial. PLoS ONE. 13(5). e0197520–e0197520. 16 indexed citations

11.

Walter, Benjamin, Peter Klare, Jens Aschenbeck, et al.. (2018). Improving the quality and acceptance of colonoscopy preparation by reinforced patient education with short message service: results from a randomized, multicenter study (PERICLES-II). Gastrointestinal Endoscopy. 89(3). 506–513.e4. 55 indexed citations

12.

Kümmel, Sherko, Stefan Paepke, Jens Huober, et al.. (2017). Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). European Journal of Cancer. 84. 1–8. 17 indexed citations

13.

Walter, Benjamin, Peter Klare, Bruno Neu, Roland M. Schmid, & Stefan von Delius. (2016). Development and Testing of an Automated 4-Day Text Messaging Guidance as an Aid for Improving Colonoscopy Preparation. JMIR mhealth and uhealth. 4(2). e75–e75. 16 indexed citations

14.

Sehouli, Jalid, Radoslav Chekerov, Alexander Reinthaller, et al.. (2016). Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR). Annals of Oncology. 27(12). 2236–2241. 24 indexed citations

15.

Klare, Peter. (2015). Patient age and duration of colonoscopy are predictors for adenoma detection in both proximal and distal colon. World Journal of Gastroenterology. 21(2). 525–525. 8 indexed citations

16.

Klare, Peter, Bernhard Haller, Anne Krug, et al.. (2015). The Impact of a Ten-Week Physical Exercise Program on Health-Related Quality of Life in Patients with Inflammatory Bowel Disease: A Prospective Randomized Controlled Trial. Digestion. 91(3). 239–247. 101 indexed citations

17.

Klare, Peter, Alexander Meining, Stefan von Delius, et al.. (2013). Argon Plasma Coagulation of Gastric Inlet Patches for the Treatment of Globus Sensation: It Is an Effective Therapy in the Long Term. Digestion. 88(3). 165–171. 15 indexed citations

18.

Schmid, Peter, R. Kreienberg, Peter Klare, et al.. (2008). Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: final results of a phase II trial. Cancer Chemotherapy and Pharmacology. 64(2). 401–406. 10 indexed citations

19.

Sehouli, Jalid, Gülten Oskay-Özcelik, Dirk Stengel, et al.. (2006). Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial. Annals of Oncology. 17(6). 957–961. 25 indexed citations

20.

Sehouli, Jalid, Dirk Stengel, Oumar Camara, et al.. (2002). A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy. Annals of Oncology. 13(11). 1749–1755. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact